IN THE SPECIFICATION

Please insert the following section at page 3, after line 28, and before line 29:

BRIEF DESCRIPTION OF DRAWINGS

Figure 1. A diagram showing the synthesis of doxorubicin-Succ-peptides.

Figure 2. A diagram showing the synthesis of doxorubicin-SMP-3MP-peptides.

Figure 3. A result of the internalization experiments for the susceptible K562 and resistant K562/ADR cells. The cells were incubated either with free doxorubicin or with doxorubicin in a vector. In the resistant K562/ADR cells, 5.68% of the cells are positive, while in the cells incubated with doxorubicin in a vector, 98% of the cells are positive, indicating the improved penetration.

Figure 4. Measuring the susceptibility of cells to anti-tumor agents using the MTT test. The activity of doxorubicin in the susceptible cells (K562) and in the resistant cells (K562/ADR) is shown. The graphic shows that the K562/ADR cells are resistant to doxorubicin.

Figure 5. Comparison of the activity of doxorubicin in a vector (compound SEQ ID NO:2) with doxorubicin added to but not linked with the peptides. The graphic shows that the IC_{50} of doxorubicin in the vector is 19 μM, while that of doxorubicin added to the vector is about 50 μM.